DIVISLAB Stock Overview
Engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
My Notes
Capture your thoughts, links and company narrative
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
Divi's Laboratories Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹5,846.75 |
| 52 Week High | ₹6,285.45 |
| 52 Week Low | ₹3,350.00 |
| Beta | 0.35 |
| 1 Month Change | -0.92% |
| 3 Month Change | 7.27% |
| 1 Year Change | 58.24% |
| 3 Year Change | 31.47% |
| 5 Year Change | 219.47% |
| Change since IPO | 66,246.10% |
Recent News & Updates
Recent updates
Revenues Not Telling The Story For Divi's Laboratories Limited (NSE:DIVISLAB)
Sep 06
Earnings Miss: Divi's Laboratories Limited Missed EPS By 9.1% And Analysts Are Revising Their Forecasts
Aug 06The Divi's Laboratories Limited (NSE:DIVISLAB) Yearly Results Are Out And Analysts Have Published New Forecasts
Jul 19Shareholders Should Be Pleased With Divi's Laboratories Limited's (NSE:DIVISLAB) Price
Apr 19Divi's Laboratories Limited (NSE:DIVISLAB) Not Flying Under The Radar
Dec 27Shareholder Returns
| DIVISLAB | IN Life Sciences | IN Market | |
|---|---|---|---|
| 7D | -0.5% | -1.3% | -4.2% |
| 1Y | 58.2% | 49.7% | 19.1% |
Return vs Industry: DIVISLAB exceeded the Indian Life Sciences industry which returned 49.7% over the past year.
Return vs Market: DIVISLAB exceeded the Indian Market which returned 19.1% over the past year.
Price Volatility
| DIVISLAB volatility | |
|---|---|
| DIVISLAB Average Weekly Movement | 3.7% |
| Life Sciences Industry Average Movement | 6.2% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: DIVISLAB has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: DIVISLAB's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 9,741 | Kiran Divi | www.divislabs.com |
Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as beta carotene, astaxanthin, lycopene, and canthaxanthin, as well as other finished forms, including lutein, and vitamins to food, dietary supplement, and feed manufacturers industries. It also exports its products.
Divi's Laboratories Limited Fundamentals Summary
| DIVISLAB fundamental statistics | |
|---|---|
| Market cap | ₹1.55t |
| Earnings (TTM) | ₹18.36b |
| Revenue (TTM) | ₹86.14b |
84.5x
P/E Ratio18.0x
P/S RatioIs DIVISLAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DIVISLAB income statement (TTM) | |
|---|---|
| Revenue | ₹86.14b |
| Cost of Revenue | ₹36.76b |
| Gross Profit | ₹49.38b |
| Other Expenses | ₹31.02b |
| Earnings | ₹18.36b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 69.16 |
| Gross Margin | 57.33% |
| Net Profit Margin | 21.31% |
| Debt/Equity Ratio | 0.04% |
How did DIVISLAB perform over the long term?
See historical performance and comparisonDividends
0.5%
Current Dividend Yield50%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 01:22 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Divi's Laboratories Limited is covered by 54 analysts. 27 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nitin Bhasin | Ambit Capital |
| Prashant Nair | Ambit Capital |
| null null | Antique Stockbroking Ltd. |